Enginprime Medical Secures $12 Million to Advance pVAD Technology Development
Enginprime Medical Secures Major Funding for pVAD Technology
In a recent development, Enginprime Medical, a pioneering company in the field of percutaneous ventricular assist devices (pVAD), has announced the successful closure of a Series A financing round that raised $12 million. This substantial fund is expected to propel the advancement of their flagship product, OpusOne™, further establishing its presence in the growing market for cardiac assist devices.
The Significance of Series A Financing
The funding round was led exclusively by Qiming Venture Partners, a venture capital firm well-known for its investments in promising health technology ventures. The capital raised during this round will support critical activities including the registration clinical trial for OpusOne™ in China, as well as regulatory submissions and the early-stage clinical development of the overall platform.
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.